Sector News

Amgen trims 172 more jobs, this time in operations, R&D and sales

November 20, 2019
Life sciences

Amgen’s top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now says it’s cutting 172 staffers at its headquarters and in the field.

The layoffs will hit R&D, operations and commercial employees, Amgen said in a California WARN filing (PDF). The majority of the jobs targeted are field-based jobs throughout the U.S., though some cuts will hit its headquarters in Thousand Oaks, California.

The layoffs will take effect Dec. 31, the filing said.

An Amgen spokeswoman said the company, like others, “regularly evaluates and adjusts staffing levels to meet the needs of the business.”

“While these decisions are never easy, we believe our ability to compete will be strengthened by a tighter focus on investments that can help bring important medicines to patients to treat serious, life-threatening illnesses,” she added.

The cuts come as Amgen deals with patent expirations and new biosimilar rivals. The company faces generic versions of its thyroid drug Sensipar and recently launched copycats to its white blood cell boosters Neupogen and Neulasta—plus anemia drug Epogen. Biosimilar versions of its immunology med Enbrel are approved but not yet launched. Amgen defeated a patent challenge on Enbrel from Sandoz over the summer.

Thanks to new rivals, the drugmaker’s sales dipped 2% in the second quarter and 3% in the third quarter versus the same periods last year.

Meanwhile, as biosims take a toll on its drugs, the company is hitting back with its own biosimilars to other companies’ blockbusters—and those meds brought in $173 million last quarter.

Last week, Amgen said it’d cut 149 jobs in Massachusetts by the end of the year as it exits neuroscience R&D.

Amgen in 2014 laid off 2,900 employees in a major restructuring, and the company in 2017 cut jobs as part of a plan to shift employment to a new facility in Tampa.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach